Enliven Therapeutics, Inc.
ELVN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,059 | $492 | $102 | $70 |
| - Cash | $124 | $100 | $76 | $110 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $935 | $392 | $27 | -$40 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$104 | -$83 | -$39 | -$25 |
| % Margin | – | – | – | – |
| Net Income | -$89 | -$72 | -$38 | -$25 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.89 | -2.01 | -6.03 | -3.17 |
| % Growth | 6% | 66.7% | -90.2% | – |
| Operating Cash Flow | -$73 | -$61 | -$32 | -$19 |
| Capital Expenditures | -$0 | -$0 | -$1 | -$0 |
| Free Cash Flow | -$73 | -$61 | -$33 | -$19 |